FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
This article was originally published in The Tan Sheet
Executive Summary
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
You may also be interested in...
Conflict Of Interest Reform Fight Reignites Following Panel Revelations
Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.
Conflict Of Interest Reform Fight Reignites Following Panel Revelations
Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.
Flurries Of New Bills Advance Device Industry Interests In Congress
The first legislative salvos were launched last week in a battle that is sure to escalate in conjunction with device user fee reauthorization efforts next year.